Breast cancer

27 August 2015

New blood test for early detection of cancer relapse

A simple blood test has the potential to accurately predict which patients will relapse from breast cancer – much earlier than is currently possible.

An experimental blood test may be able to predict whether a woman with breast cancer will suffer a relapse months before new tumours would be detectable on scans, researchers said.

Read: Breast cancer: myths and facts 

The technology, described in the journal Science Translational Medicine, works by detecting cancer DNA that circulates in the bloodstream.

Used to predict relapse

While the test is not yet available to the public, and likely will not be for years to come, researchers are hopeful that it could help refine personalised treatments for cancer and perhaps lead scientists further down the path of finding a cure one day.

Read: How to do a breast self exam

"We have shown how a simple blood test has the potential to accurately predict which patients will relapse from breast cancer, much earlier than we can currently," said study author Nicholas Turner, team leader in molecular oncology at The Institute of Cancer Research, London.

"Ours in the first study to show that these blood tests could be used to predict relapse," he added.

Scientists took tumour and blood samples from 55 breast cancer patients with early-stage disease. Each of the patients had received chemotherapy and surgery to remove the cancer.

The blood test was administered following surgery and every six months afterward as a follow-up.

Of the 15 women who saw their cancer return, the test accurately predicted that relapse in 12 of them.

The test also detected cancer an average of about eight months earlier than the tumours were visibly detectable on conventional scans.

Potentially available in hospitals

The technique uses personalised digital polymerase chain reaction (dPCR) tests to track mutations and could be applied to all subtypes of breast cancer, the study said.

Turner said there are some technical challenges to implementing the technology, "but digital PCR is relatively cost-effective and the information that it provides could make a real difference to breast cancer patients."

Breast cancer is diagnosed early in 95 percent of cases, but knowing whether or not treatment is able to remove all signs of cancer is key to preventing the tumours from returning and spreading elsewhere in the body.

"It will be some years before the test could potentially be available in hospitals, but we hope to bring this date closer by conducting much larger clinical trials starting next year," Turner said.

Read more:

Afrikaners may be more likely to carry Angelina Jolie's breast cancer gene

Paget's disease of the nipple

Freezing tumours shows promise against prostate, breast cancer

Image: Breast examination from iStock


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules